nbi-6024

Peptideexperimental

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2001 (NCT00873561)

Timeline

2000s

Jan 1, 2001
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Diabetes Mellitus, Type 1 · Phase 1

Mechanism of action

Insulin-like growth factor I receptorAGONIST
IGF1R agonist
- Insulin-like growth factor 1 receptor (IGF1R) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C

Mol. weight: 1521.74 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297306 ↗

Also known as

nbi6024
nbi-6024
nbi-6024
nbi-6024
nbi-6024

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00873561	Phase 1	Dec 1, 2001	Neurocrine Biosciences, New Groote Schuur Hospital, Cape Town

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Neurocrine Biosciences	For profit	1	1	1	2001
New Groote Schuur Hospital, Cape Town	Academic/Hospital	1	0	1	2001

2 organizations

Page 1 / 1